Page 20 - Haematologica July

Editorials
1098
Additionally, the negative impact of genomic complexity as measured by complex karyotype18 or multiple driver mutations19,20 has become increasingly clear, and these fea- tures would likely add further nuance to a patient-specific risk stratification. Increasingly, I take into account all of these disease features, as well as the patient’s age, general health, preferences and reason for needing therapy, when considering their therapeutic options. The time has come for clinical trials and long-term population-based studies informed by this deeper risk stratification in order to understand the natural history of sequential therapy choices in these increasingly differentiated unique patient subgroups. Only in this way can we best serve and advise our patients among the myriad of choices.
References
1 Cuneo A, Follows G, Rigolin GM, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209-1217.
2. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-23.
3. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-2437.
4. Gordon M, Churnetski M, Alqahtani H, et al. Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib. Cancer. 2018 [In press]
5. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analy- sis. Haematologica. 2018;103(5):874-879.
6. O'Brien S, Furman RR, Coutre S, et al. Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience. Blood. 2018;131(17):1910-1919.
7. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rit- uximab in patients with relapsed and/or refractory chronic lymphocyt- ic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559- 3566.
8. Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage out- comes in patients with first relapse after fludarabine, cyclophos- phamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90(6):511-514.
9. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32- 42.
10. BrownJR,HillmenP,O'BrienS,etal.Extendedfollow-upandimpact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83-91.
11. O'BrienS,ByrdJ,HillmenP,etal.Outcomeswithibrutinibbylineof therapy in patients with CLL: Analyses from phase III data. J Clin Oncol. 2016;34(suppl):Abstr 7520.
12. Chanan-KhanA,CramerP,DemirkanF,etal.Ibrutinibcombinedwith bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
13. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297-311.
14. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107-1120.
15. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
16. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-ritux- imab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921- 1924.
17. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophos- phamide, and rituximab treatment achieves long-term disease-free sur- vival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303-309.
18. Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibruti- nib-based regimens. Cancer. 2015;121(20):3612-3621.
19. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574): 525-530.
20. Puente XS, Bea S, Valdes-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519-524.
haematologica | 2018; 103(7)